To reinforce the roles of c-Myc/PRMT5 as downstream effectors, we used c-Myc inhibitor or PRMT5 inhibitor for in vivo treatment in the pancreatic cancer liver metastasis model bearing TLR3 knockout cancer cells with NLS-TLR3 rescue. Here, MYC is linked to cancer.